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Abstract
Background: The variable number tandem repeat (VNTR) polymorphism 5-repeat allele of the circadian gene PERIOD3
(PER3
5/5) has been associated with cognitive decline at a specific circadian phase in response to a night of total sleep
deprivation (TSD), relative to the 4-repeat allele (PER3
4/4). PER3
5/5 has also been related to higher sleep homeostasis, which is
thought to underlie this cognitive vulnerability. To date, no study has used a candidate gene approach to investigate the
response to chronic partial sleep deprivation (PSD), a condition distinct from TSD and one commonly experienced by
millions of people on a daily and persistent basis. We evaluated whether the PER3 VNTR polymorphism contributed to
cumulative neurobehavioral deficits and sleep homeostatic responses during PSD.
Methodology/Principal Findings: PER3
5/5 (n=14), PER3
4/5 (n=63) and PER3
4/4 (n=52) healthy adults (aged 22–45 y)
demonstrated large, but equivalent cumulative decreases in cognitive performance and physiological alertness, and
cumulative increases in sleepiness across 5 nights of sleep restricted to 4 h per night. Such effects were accompanied by
increasing daily inter-subject variability in all groups. The PER3 genotypes did not differ significantly at baseline in habitual
sleep, physiological sleep structure, circadian phase, physiological sleepiness, cognitive performance, or subjective
sleepiness, although during PSD, PER3
5/5 subjects had slightly but reliably elevated sleep homeostatic pressure as measured
physiologically by EEG slow-wave energy in non-rapid eye movement sleep compared with PER3
4/4 subjects. PER3 genotypic
and allelic frequencies did not differ significantly between Caucasians and African Americans.
Conclusions/Significance: The PER3 VNTR polymorphism was not associated with individual differences in neurobehavioral
responses to PSD, although it was related to one marker of sleep homoeostatic response during PSD. The comparability of
PER3 genotypes at baseline and their equivalent inter-individual vulnerability to sleep restriction indicate that PER3 does not
contribute to the neurobehavioral effects of chronic sleep loss.
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Introduction
Subjects undergoing total sleep deprivation (TSD) display
differential vulnerability to sleep loss, demonstrating robust inter-
individual differences in response to the same laboratory
conditions, as measured by various neurobehavioral tasks and
physiological and subjective sleep measures sensitive to sleep loss
[1–6]. Some of these measures, including self-rated sleepiness,
habitual sleep duration and habitual bedtime show moderate
heritability [7]. Such differential vulnerability extends to chronic
partial sleep deprivation (PSD) protocols, in which sleep is
restricted to 3-7 h time in bed per night [8,9]. The stable, trait-
like inter-individual differences observed in response to TSD [1–
4]—with intraclass correlations ranging from 58–92% for
neurobehavioral measures [1,4]—point to an underlying genetic
component.
Despite this link, however, little is known about the genetic basis
of differential vulnerability to sleep loss on functioning in healthy
subjects undergoing deprivation [10,11]. Recently, two related
publications reported on the role of the variable number tandem
repeat (VNTR) polymorphism of the circadian gene PERIOD3
(PER3) in response to TSD by using a small group of subjects
(n=24 of various ethnicities) recruited specifically for the
homozygotic versions of this polymorphism. PER3 is characterized
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and shows similar allelic frequencies in African Americans and
Caucasians/European Americans [12,13]. Compared with the 4-
repeat allele (PER3
4/4; n=14), the longer, 5-repeat allele (PER3
5/
5; n=10) was associated with worse cognitive performance and
with higher sleep propensity including slow-wave activity in the
sleep EEG—a putative marker of sleep homeostasis—before and
after TSD [14]. A subsequent report on the same subjects clarified
that the PER3
5/5 performance deficits were found only on specific
executive function tests, and only at 2–4 h following the melatonin
circadian rhythm peak, from approximately 6–8 am [15]. Such
performance differences were hypothesized to be mediated by
sleep homeostasis [14,15].
Since the PER3 VNTR polymorphism predicted individual
differences in sleep-loss-induced decrements in performance and
in sleep homeostasis following a night of TSD [14,15], we sought
to determine whether this polymorphism was also associated with
cumulative performance deficits and sleep homeostatic responses
during chronic PSD—a condition experienced by millions of
people on a consecutive and daily basis [16–18], associated with
serious health consequences [16,19], and distinguished from TSD
[8,20]. Because of this distinction, different genetic polymorphisms
may influence responses to TSD and chronic PSD. To date,
however, no published study has examined the PER3 VNTR or
any other genetic polymorphism and its relationship to cumulative
neurobehavioral or homeostatic functioning in chronic PSD.
In the current study, the PER3 VNTR polymorphism was not
associated with individual differences in neurobehavioral responses
to PSD, although it was related to one marker of sleep
homoeostatic response. Equivalent baseline physiological, cogni-
tive and subjective measures and comparable inter-individual
vulnerability to PSD indicate genes other than PER3 contribute to
the cumulative behavioral effects of chronic partial sleep loss.
Results
Fifty-two PER3
4/4 (M=31.2 y67.0 y; 24 women, 20 Cauca-
sians, 31 African Americans), 63 PER3
4/5 (M=28.9 y66.3 y; 33
women, 24 Caucasians, 37 African Americans) and 14 PER3
5/5
(M=29.7 y68.2 y; 9 women, 5 Caucasians, 8 African Americans)
healthy adults were characterized for their cognitive performance,
self-rated sleepiness, executive functioning and physiological sleep
responses to a PSD protocol of 4 h time in bed for five consecutive
nights.
Demographic and Pre-study Variables
As shown in Table 1, the three PER3 genotypes did not differ
significantly in demographic variables including age, body mass
index, or sex, or in ethnicity, in terms of the genotypic and allelic
frequency between Caucasians and African Americans. Moreover,
the groups did not differ in IQ as measured by the North American
Adult Reading Test [21], or in psychosocial/personality traits, as
measured by the Beck Depression Inventory [22] and the Eysenck
Personality Inventory, extraversion subscale [23]. In addition, pre-
study sleep duration, onset and offset (determined by wrist actigraphy
for one week prior to study entry) and circadian rhythm phase
markers (Morningness-Eveningness chronotype [24] and actigraphic
sleep midpoint) were not significantly different across genotypes.
Cognitive Performance
Chronic PSD induced significant deficits in neurobehavioral
performance across days as shown by increases in lapses (.500 ms
reaction times) on the Psychomotor Vigilance Test [PVT; 25–27],
a well-validated vigilant attention task (Figure 1A), and by
increasing variability for all 3 groups across chronic PSD days
(Figure 1A). Although all genotypes significantly increased the
number of lapses across days (F2.46, 310.29=55.35, p,0.001), there
Table 1. Characteristics of PER3
4/4, PER3
4/5 and PER3
5/5 Subjects (Mean6SD).
Characteristic PER3
4/4 PER3
4/5 PER3
5/5 p
*
N 52 63 14
Age 31.267.0 28.966.3 29.768.2 0.191
BMI (kg/m
2) 25.5063.54 24.1963.57 23.7562.39 0.076
Sex (M/F) 28/24 30/33 5/9 0.473
Ethnicity (Caucasian/African American/Other)
# 20(.41)/31(.41)/1(.25) 24(.49)/37(.49)/2(.50) 5(.10)/8(.10)/1(.25)
Morningness-Eveningness Composite Scale 40.4765.63
a 39.0065.44 41.8666.50 0.154
Beck Depression Inventory (BDI) 1.3561.96
b 1.6962.51
d 1.1462.03 0.600
Eysenck Personality Inventory (Extraversion subscale) 15.1664.04
c 15.7363.64
e 14.5064.03 0.505
North American Adult Reading Test (IQ) 107.1068.61
c 105.3067.97
f 104.5766.69 0.410
Sleep Onset
** 23:4960.93 h
c 23:5860.92 h 23:4060.85 h 0.462
Sleep Offset
** 07:4660.90 h
c 08:0061.00 h 07:4060.85 h 0.296
Sleep Midpoint
** 03:5860.35 h
c 04:0160.35 h 03:5960.27 h 0.826
Total Sleep Time
** (Sleep Duration) 7.9660.73 h
c 8.0660.74 h 8.0060.55 h 0.780
an=49.
bn=51.
cn=50.
dn=62.
en=59.
fn=60.
*p values are for the comparison of the three genotypes.
**Determined by wrist actigraphy (one week prior to study entry).
#Genotypic frequencies are in parentheses. 4-repeat allele frequency was 650 and 5-repeat allele frequency was 350 for both Caucasians and African Americans.
doi:10.1371/journal.pone.0005874.t001
PER3 and Chronic Deprivation
PLoS ONE | www.plosone.org 2 June 2009 | Volume 4 | Issue 6 | e5874were no differential responses in PVT lapses (day6genotype:
F4.93, 310.29=0.31, p=0.907) nor did one group show more lapses
than the other groups across days (genotype: F2,126=0.67,
p=0.514). Moreover, PVT lapses showed no significant baseline
(F2,126=0.63, p=0.533) or sleep deprivation (F2,126=1.23,
p=0.296) differences (Table 2).
As shown in Figure 1B, the 3 groups showed no differential
changes on Digit Symbol Substitution Task [DSST; 28]
Figure 1. Neurobehavioral performance at baseline and during chronic partial sleep deprivation for the PER3 groups. Mean (6SEM)
(A) PVT lapses (.500 ms reaction times) per trial, (B) total number correct per trial on the Digit Symbol Substitution Task (DSST) and (C) Digit Span
(DS) task, and scores per trial on the (D) Karolinska Sleepiness (KSS) and (E) ‘‘Fresh-Tired’’ Visual Analog Scale (VAS) at baseline (B) and each partial
sleep deprivation/restriction night (SR1-SR5) for PER3
4/4 (open circles), PER3
4/5 (gray triangles) and PER3
5/5 (closed circles) subjects. Although all
genotypes showed increased PVT lapses and variability across chronic PSD, there were no differential responses in lapses nor did one genotype show
more lapses than the other groups at baseline or during chronic PSD. PER3
5/5 subjects had better cognitive throughput than their PER3
4/4
counterparts, as indicated by significantly higher DSST scores across days; there were no differential changes in DSST scores across chronic PSD or
significant changes across days. For all groups, DS total correct scores significantly decreased, and KSS and VAS scores significantly increased across
chronic PSD, but there were no differential changes or group differences in these measures during chronic PSD.
doi:10.1371/journal.pone.0005874.g001
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p=0.163) nor did scores change significantly across days (day: F2.90,
365.01=1.55, p=0.163). Although the DSST did not show 3-group
differences (genotype: F2,126=2.37, p=0.098),comparison of the two
homozygote groups only—an approach used by Viola et al. [14]—
showed that PER3
5/5 subjects had better cognitive throughput than
their PER3
4/4 counterparts in response to chronic PSD (in contrast to
data from Violaet al.[14]),as indicated by significantly higher DSST
scores across days (genotype: F1,64=3.96, p=0.050). These two
groups showed no differences in baseline DSST scores (F1,64=2.37,
p=0.128), but PER3
5/5 subjects had significantly higher scores across
the 5 PSD nights (F1,64=4.40, p=0.040). By contrast, overall
performance on the Digit Span (DS) task, a test of working memory
storage capacity [28], significantly decreased across days for all
groups (day: F2.78, 349.52=4.51, p=0.005), although there were no
differential changes (day6genotype: F5.55, 349.52=0.59, p=0.722) or
group differences (genotype: F2,126=1.46, p=0.237) in this measure
(Figure 1C). Moreover, DS forward, backward and total correct
scores showed no baseline (forward: F2,126=1.73, p=0.181;
backward: F2,126=0.87, p=0.423; total: F2,126=1.38, p=0.255) or
chronic PSD (forward: F2,126=1.66, p=0.194; backward:
F2,126=1.03, p=0.359; total: F2,126=1.37, p=0.259) differences
(Table 2).
Subjective and Physiological Sleepiness
Chronic PSD produced significant increases in subjective
sleepiness across days as shown by increases in Karolinska
Sleepiness Scale [KSS; 29] scores for all genotypes (Figure 1D;
day: F2.96, 373.33=103.23, p,0.001). Despite such increased scores
across chronic PSD, there were no differential responses in
sleepiness ratings (day6genotype; F5.93, 373.33=0.54, p=0.778)
nor did one group have higher ratings than the other groups across
days (genotype: F2,126=1.93, p=0.150). Scores on the ‘‘Fresh-
Tired’’ visual analog scale [VAS; 30] showed similar results
(Figure 1E; day: F2.42, 304.95=79.38, p,0.001; day6genotype:
F4.84, 304.95=1.20, p=0.310; genotype: F2,126=2.44, p=0.090).
Notably, neither self-rating scale showed chronic PSD differences
across genotypes (KSS: F2,126=1.63, p=0.200; VAS:
F2,126=2.18, p=0.118; Table 2). While the KSS showed no
baseline group differences (F2,126=2.75, p=0.068), the VAS
showed a small but reliable difference at baseline (F2,126=3.59,
p=0.031), with PER3
4/5 subjects rating themselves as more
fatigued than PER3
4/4 subjects (Bonferroni correction, p=0.025).
Substantiating the self-rated sleepiness data, a modified version
of the Maintenance of Wakefulness Test [MWT; 17,31]—a
measure of the ability to resist sleep—also did not differ
significantly across groups or show differential changes to chronic
PSD, although all three genotypes were significantly less able to
resist sleep as a result of chronic PSD (day: F1,87=35.71, p,0.001;
day6genotype: F2,87=1.72, p=0.186; genotype: F2,87=2.11,
p=0.130). The groups did not differ across chronic PSD
(F2,87=0.25, p=0.777; Table 2), but showed a slight but reliable
difference at baseline (F2,87=3.24, p=0.044), with the PER3
4/5
group showing a reduced ability to resist sleep compared with the
PER3
4/4 group (Bonferroni correction, p=0.050).
Executive Function Measures
The Hayling [32; Figure 2A; F2,105=0.25, p=0.779], the
Brixton [32; Figure 2B; F2,108=2.28, p=0.107] and the
Controlled Oral Word Association Tests [33; COWAT;
Figure 2C; F2,101=0.98, p=0.379]—all executive function tests
measured at SR5—failed to show significant differences across the
PER3 genotypes. Similarly, the 3 PER3 genotypes did not
significantly differ on measures derived from the Tower of London
(TOL), an executive function test that assesses planning abilities
[34; Figure 3; A: F2,107=0.57, p=0.566; B: F2,107=0.26,
p=0.770; C: F2,107=0.61, p=0.543; D: F2,107=0.16, p=0.855;
E: F2,107=0.43, p=0.654; F: F2,107=0.17, p=0.845; G:
F2,107=0.21, p=0.809].
Sleep Physiology
The PER3 variants did not differ significantly in any
polysomnographic (PSG) sleep measure at baseline, at SR1 or at
SR5 (Table 3). Across genotypes, however, PSG variables
displayed an acute response to chronic PSD in a manner
consistent with sleep loss and concomitant increases in homeostatic
Table 2. Cognitive and Sleepiness Measures at Baseline and Across Sleep Restriction in PER3
4/4, PER3
4/5 and PER3
5/5 Subjects
(Mean6SD).
Measure Baseline Sleep Restriction (SR1-SR5)
PER3
4/4 PER3
4/5 PER3
5/5 p* PER3
4/4 PER3
4/5 PER3
5/5 p
*
Cognitive Measures
PVT (lapses) 2.1262.75 2.8363.15 3.2762.91 0.296 6.5566.21 7.6366.05 8.1965.77 0.533
DSST (# correct) 55.5969.52 55.1769.70 60.0369.79 0.229 55.6969.20 55.17610.12 61.5669.58 0.082
DS Forward (# correct) 5.5660.97 5.1861.04 5.3661.48 0.181 5.4460.99 5.0661.08 5.2661.61 0.194
DS Backward (# correct) 4.4761.21 4.1561.46 4.4761.59 0.423 4.3461.27 4.0361.39 4.4661.46 0.359
DS Total (# correct) 10.0361.98 9.3362.31 9.8362.95 0.255 9.7862.11 9.1062.33 9.7262.98 0.259
Sleepiness Measures
KSS (score) 2.9661.31 3.5561.39 3.3961.42 0.068 5.1361.62 5.5561.51 5.8361.48 0.200
VAS (score) 2.7061.35 3.3561.21
{ 3.0161.39 0.031 4.8361.29 4.6861.34 4.1761.57 0.118
MWT
** (min) 22.58610.02 16.81610.23
{ 21.59611.80 0.044 11.3069.05 10.4968.71 12.5369.60 0.777
*p values are for the comparison of the three genotypes
{Different from PER3
4/4,p #0.05, Bonferroni correction
**Modified version administered once at Baseline and once at SR5 only; PER3
4/4 (n=33), PER3
4/5 (n=46), PER3
5/5 (n=11).
Abbreviations: Psychomotor Vigilance Test (PVT); Digit Symbol Substitution Task (DSST); Digit Span (DS) task; Karolinska Sleepiness Scale (KSS); ‘‘Fresh-Tired’’ Visual
Analog Scale (VAS); Maintenance of Wakefulness Test (MWT).
doi:10.1371/journal.pone.0005874.t002
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(slow-wave) sleep, and amount of REM sleep significantly
increased with chronic PSD; by contrast, TST, sleep onset
latency, REM latency, WASO, and amounts of stage 1 and stage 2
sleep significantly decreased with chronic PSD (Table 3). There
were no differential changes in PSG measures in response to
chronic PSD and no reliable main effects of genotype for any PSG
variable.
Similarly, across the baseline night, the three genotypes did not
differ significantly in slow-wave energy (SWE) of the delta band in
NREM sleep calculated from the C3 (Figure 4A; genotype:
F2,89=0.79, p=0.458), Fz (Figure 4C; genotype: F2,95=1.91,
p=0.154) and O2 (Figure 4F; genotype: F2,98=0.20, p=0.822)
EEG derivations. SWE significantly dissipated across the baseline
night for all channels (C3: hour: F3.15, 280.59=101.28, p,0.001; Fz:
hour: F2.49, 236.41=85.55, p,0.001; O2: hour: F1.92, 188.45=44.19,
p,0.001), but not in a differential pattern across genotypes (C3:
hour6genotype: F6.31, 280.59=1.68, p=0.123; Fz: hour6genotype:
F4.98, 236.41=2.18, p=0.119; O2: hour6genotype: F3.85, 188.45=
1.72, p=0.210).
Slow-wave activity (SWA) also showed no significant differences
across the baseline night as calculated from the C3 (Figure 4B;
genotype: F2,89=0.09, p=0.913), Fz (Figure 4D; genotype:
F2,95=1.09, p=0.340) and O2 (Figure 4F; genotype: F2,98=0.34,
p=0.714) EEG derivations. SWA significantly dissipated across the
baseline night for all channels (C3: hour: F2.82, 250.78=88.21,
p,0.001; Fz: hour: F1.93, 183.27=55.18, p,0.001; O2: hour:
F1.81, 177.61=36.91, p,0.001), but not in a differential pattern across
genotypes (C3: hour6genotype: F5.64, 250.78=1.17, p=0.326; Fz:
hour6genotype: F3.86, 183.27=1.22, p=0.304; O2: hour6genotype:
F3.63, 177.61=1.40, p=0.239).
SWE and SWA displayed acute responses to chronic PSD in all
genotypes, as evidenced by percentage increases above the
corresponding baseline hour for all channels (Figure 5). SWE %
baseline and SWA % baseline derived from C3 showed significant
changes across chronic PSD (SWE % baseline, hour: F1.87,
181.12=4.41, p=0.015; SWA % baseline, hour: F2.07, 200.29=4.99,
p=0.007; Figure 5A, 5B), as did SWE % baseline and SWA %
baseline derived from Fz (SWE % baseline, hour:
F2.29,217.75=4.55, p=0.009; SWA % baseline, hour:
F1.79,172.00=3.07, p=0.050; Figure 5C, 5D) while measures
derived from the O2 channel were not significant (SWE O2 %
baseline, hour: F2.27,215.19=0.16, p=0.874; SWA O2 % baseline,
hour: F2.15,201.80=0.30, p=0.756; Figure 5E, 5F).
SWE % baseline and SWA % baseline failed to show significant
differential changes across chronic PSD for the PER3 genotypes in
the C3 EEG derivation (SWE % baseline: hour6genotype:
F3.73,181.12=3.73, p=0.717; SWA % baseline: hour6genotype:
F4.13,200.29=0.51, p=0.732; Figure 5A, 5B), Fz (SWE % baseline:
hour6genotype: F4.58,217.75=2.19, p=0.062; SWA % baseline:
hour6genotype: F3.58,172.00=2.00, p=0.105; Figure 5C, 5D), or
O2 EEG derivations (SWE % baseline: hour6genotype: F4,53=1.05,
p=0.388; SWA % baseline: hour6genotype: F4.29,201.80=1.08,
p=0.369; Figure 5E, 5F). SWE % baseline derived from the C3
channel was slightly but significantly higher during chronic PSD for
PER3
5/5 compared with PER3
4/4 and PER3
4/5 subjects (SWE %
baseline: genotype: F2,97=4.45, p=0.014; Bonferroni correction,
p,0.05; Figure 5A). There were no significant 3-group differences
detected in SWA % baseline derived from C3 (SWA % baseline:
genotype: F2,97=1.09, p=0.341; Figure 5B), or in SWE % baseline
a n dS W A%b a s e l i n ed e r i v e df r o mt h eF z( S W E%b a s e l i n e :
genotype: F2,95=0.43, p=0.651; SWA % baseline: genotype:
F2,96=0.76, p=0.471; Figure 5C, 5D) or O2 channels (SWE %
baseline: genotype: F2,95=1.81, p=0.170; SWA % baseline:
genotype: F2,94=1.51, p=0.227; Figure 5E, 5F).
Discussion
During chronic partial sleep deprivation, PER3
5/5 subjects
exhibited slightly but reliably higher slow-wave activity and slow-
Figure 2. Executive function task performance after five nights
of partial sleep deprivation for the PER3 groups. Mean (6SD) (A)
Hayling scaled scores, (B) Brixton scaled scores and (C) Controlled Oral
Word Association Test (COWAT) word production per letter at SR5 for
PER3
4/4 (A: n=47; B: n=48; C: n=46), PER3
4/5 (A: n=50; B: n=52; C:
n=47) and PER3
5/5 (n=11) subjects. Higher scores indicate better
performance on all tasks. None of these executive function tests
showed significant differences across the PER3 genotypes (ps .0.05).
doi:10.1371/journal.pone.0005874.g002
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4/4 subjects. All three PER3 VNTR
genotypes, however, demonstrated robust and equivalent cumu-
lative decreases in cognitive performance and physiological
alertness, and cumulative increases in sleepiness across chronic
PSD, with increasing daily inter-subject variability. The genotypes
showed no differences at baseline in habitual sleep, physiological
sleep structure, circadian phase, physiological sleepiness, cognitive
performance, or subjective sleepiness. Thus, collectively, we
conclude the PER3 VNTR polymorphism is not associated with
differential vulnerability to the neurobehavioral effects of chronic
PSD, although it is related to sleep homeostatic responses.
Consequently, this polymorphism may be critical to behavioral
performance only when sleep is entirely absent at a specific
circadian phase in the early morning hours (i.e., from 6–8 am).
Moreover—since the genotypes were comparable at baseline and
showed equivalent inter-individual vulnerability to partial sleep
deprivation—PER3 does not contribute to the cumulative
neurobehavioral effects of chronic partial sleep loss.
Our chronic PSD protocol produced robust changes in
cognitive performance, standard sleepiness and wakefulness
measures, and physiological sleep measures characteristic of
cumulative sleep loss studies conducted in various laboratories
[3,8,9,18,20,35–40], thus validating our experimental approach.
We detected poorer performance on the DS working memory
capacity test, the first study to report such a cumulative change,
and on the PVT, with variability of lapses increasing for all
genotypes across PSD days, and greater self-rated and physiolog-
ical sleepiness across the five days of PSD—but not differentially
so—in PER3
5/5 subjects.
PER3
5/5 subjects had slightly but reliably better cognitive
throughput than their PER3
4/4 counterparts, as indicated by
significantly higher DSST scores across all 5 PSD nights. Our data
contrast with two TSD studies which found that PER3
5/5
individuals showed poorer outcomes on a waking performance
composite [14] and on specific executive function tasks, but did
not differ on the DSST [15]. Since our version of the DSST
contained nine symbols and digits instead of eight, and it was
longer, as determined from mean data presented in [15], the
reasons for this discrepancy remain unclear, but may be
methodological or due to differences produced by TSD versus
chronic PSD conditions.
SWA and SWE—putative markers of sleep homeostasis—were
higher after chronic PSD. In contrast to Viola et al.’s TSD study
[14], however, we found no evidence for differential responses to
chronic PSD between PER3
5/5 and PER3
4/4 subjects; this may be
due to the nature of such PSD paradigms, in which mitigation of
homeostasis occurs via partial daily sleep recuperation [8,20].
Since overall homeostatic differences were small between PER3
5/5
and PER3
4/4 subjects during chronic PSD, and there were no
differential increases as a result of sleep loss, PER3 is not the
exclusive genetic determinant of the homeostatic response to
chronic PSD. In addition, because homeostatic differences
occurred during the biological night, other genetic polymor-
phisms—including clock gene polymorphisms [41,42]—may
influence differential vulnerability to SWA and SWE changes
resulting from chronic PSD.
Our study suggests that PER3
5/5 subjects may have higher sleep
need under chronic PSD conditions, but not at baseline, in
contrast to data from Viola et al. [14]. The baseline discrepancies
may be explained by a sleep debt factor inherent to a difference in
design between studies. In our study, for the first two nights
(baseline), all subjects received 10 h time in bed from 2200–0800 h
to reduce any pre-existing sleep debt prior to chronic PSD.
Baseline was preceded by average pre-study sleep durations of
approximately 8 h in both groups; thus, our examination of
baseline sleep was completed under fully-rested homeostatic
pressure conditions. By contrast, since subjects in the Viola et al.
[14] study had on average .5–1 h less sleep prior to entry (7–7.5 h
sleep duration), they were not given any saturation nights, and
their baseline sleep was curtailed to between 6.78–7.45 h time in
bed (for PER3
5/5 and PER3
4/4, respectively), they likely still
harbored a significant lingering sleep debt. As such, protocol
artifact and differential preexisting sleep debt—rather than true
endogenous variations—may explain reported baseline differences
in sleep propensity and sleep homeostatic measures between the
PER3
5/5 and PER3
4/4 genotypes.
PER3
5/5 subjects showed higher homeostatic pressure during
sleep chronic PSD, but not poorer cognitive, executive functioning
or subjective sleepiness responses to chronic PSD. Such a
separation of responses has been noted in other studies in which
the homeostatic sleep responses to chronic PSD and TSD have not
been reflected in waking neurobehavioral or cognitive responses
[8,43,44]. These findings suggest that distinct genetic polymor-
phisms mediate differential vulnerability to cognitive and subjec-
tive sleepiness changes resulting from chronic PSD.
Despite prior studies showing that the PER3 VNTR polymor-
phism is associated with diurnal preference and delayed sleep
phase syndrome [45–48], we found no significant genotype
differences in circadian phase as measured by chronotype.
Similarly, we found no differences in our other measure of
circadian phase, the actigraphic sleep midpoint. Our results
concur with more recent reports that utilized both physiological
and self-rated circadian measures [14,15], and they may be due to
a lack of power to detect such differences in smaller sample size
studies, or may highlight false positives in earlier studies [45–48].
Notably, we found no differences in executive functioning
following five nights of chronic PSD. The COWAT, which
measures verbal fluency and orthographic lexical retrieval, and
involves the dorsolateral and prefrontal cortex, showed no
differences in word production [49,50]. The genotypes showed
no differences in performance on the Hayling and Brixton tests,
which measure basic task initiation speed and response suppres-
sion performance, and detection of and ability to follow rules,
respectively. Poor performance on these tests is associated with
frontal lobe dysfunction and dysexecutive symptoms [32,51,52].
Moreover, all groups performed equivalently on various perfor-
mance outcomes of the TOL, which measures executive planning
and problem solving abilities, and involves the prefrontal cortex
[53]. Thus, across a variety of executive function tasks, PER3
5/5
subjects performed at par with PER3
4/4 and PER3
4/5 subjects, in
contrast to results from a previous study indicating executive
functioning impairment in this group [15].
Figure 3. Tower of London performance after five nights of partial sleep deprivation for the PER3 genotypes. Mean (6SD) Tower of
London (TOL) performance measures at SR5 for PER3
4/4 (n=46), PER3
4/5 (n=53) and PER3
5/5 (n=11) subjects. (A) total correct; (B) total moves; (C)
initiation time (secs); (D) execution time (secs); (E) total time (secs); (F) total time violations; (G) total rule violations. In all panels except (A), lower
values indicate better performance; thus, the top of the ordinate represents better performance. None of the TOL performance measures showed
significant differences across the PER3 genotypes (ps .0.05).
doi:10.1371/journal.pone.0005874.g003
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PLoS ONE | www.plosone.org 8 June 2009 | Volume 4 | Issue 6 | e5874In the Groeger et al. study [15], the performance deficits posited
to be mediated by the PER3 VNTR polymorphism occurred
selectively only at two time points—2–4 h after the midpoint of the
circadian melatonin rhythm—approximately from 6–8 am. We
could not collect data after the 0200 h test bout, since our subjects
were asleep from 0400–0800 h on each of the PSD nights. Thus,
our results cannot be directly compared with the findings of
Groeger et al. [15]. However, such selective findings—both in
Figure 4. Hourly slow-wave energy and slow-wave activity during baseline for the PER3 genotypes. Mean (6SEM) hourly slow-wave
energy (SWE) and slow-wave activity (SWA) derived from the C3 (A, B), Fz (C, D) or O2 (E, F) channels at baseline for PER3
4/4 (open circles), PER3
4/5 (gray
triangles) and PER3
5/5 (closed circles) subjects. SWE and SWA significantly dissipated across the baseline night for all 3 channels, but not in a differential
pattern across genotypes. In addition, the genotypes did not show significant differences in SWE or SWA derived from the C3, Fz or O2 channels.
doi:10.1371/journal.pone.0005874.g004
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PLoS ONE | www.plosone.org 9 June 2009 | Volume 4 | Issue 6 | e5874terms of time of day and executive tests affected—indicate that
other genetic polymorphisms may influence executive function
and cognitive performance deficits resulting from TSD.
In summary, the PER3
4/4, PER3
4/5 and PER3
5/5 genotypes
demonstrated comparable cumulative increases in sleepiness and
cumulative decreases in cognitive performance and physiological
Figure 5. Slow-wave energy and slow-wave activity during chronic partial sleep deprivation for the PER3 genotypes. Mean (6SEM)
hourly slow-wave energy (SWE) and slow-wave activity (SWA) as a percentage of baseline at the same corresponding hour derived from the C3 (A, B),
Fz (C, D) or O2 (E, F) channels at partial sleep deprivation/restriction night 1 (SR1) and partial sleep deprivation/restriction night 5 (SR5) for hour 1 (H1)
and hour 2 (H2) in PER3
4/4 (open circles), PER3
4/5 (gray triangles) and PER3
5/5 (closed circles) subjects. SWE derived from C3 (but not from Fz or O2) was
significantly higher during chronic PSD in PER3
5/5 compared with PER3
4/4 and PER3
4/5 subjects.
doi:10.1371/journal.pone.0005874.g005
PER3 and Chronic Deprivation
PLoS ONE | www.plosone.org 10 June 2009 | Volume 4 | Issue 6 | e5874alertness, across five nights of chronic PSD, with all genotypes
showing increasing daily inter-subject variability. During chronic
PSD, PER3
5/5 subjects exhibited slightly but reliably higher SWA
and SWE than PER3
4/4 subjects. In contrast to published data in
TSD paradigms, PER3 polymorphism variants did not differ on
baseline sleep measures or in their physiological sleepiness,
cognitive, executive functioning or subjective responses to chronic
PSD. Thus, the PER3 VNTR polymorphism is not a genetic
marker of differential vulnerability to the cumulative neurobehav-
ioral effects of chronic PSD. We propose that other genes—both
circadian and non-circadian—regulate neurobehavioral responses
to chronic PSD. Our study is the first to characterize the role of
any genetic polymorphism in response to chronic PSD, a
condition experienced by millions of individuals persistently and
daily due to work, travel and social obligations, and one associated
with a wide range of serious health consequences. As such, this
study provides a foundation for future studies using a candidate
gene approach to investigate neurobehavioral and homeostatic
responses to chronic partial sleep deprivation.
Materials and Methods
Subjects
One hundred and twenty-nine subjects participated in one of
two chronic PSD experiments (described below). Following
protocol completion, all subjects were genotyped for the PER3
VNTR polymorphism [PER3
4/4: n=52; mean6SD;
31.2 yr67.0 yr; 24 women; PER3
4/5: n=63; mean6SD;
28.9 yr66.3 yr; 33 women; PER3
5/5: n=14; mean6SD;
29.7 yr68.2 yr; 9 women; see Table 1]. The percentage of each
of our three PER3 VNTR genotypes approximated those reported
by Viola et al. [14]. In order to be eligible for study participation,
subjects met the following inclusionary criteria: age range from
22–45 yrs; physically and psychologically healthy, as assessed by
physical examination and history; no clinically significant
abnormalities in blood chemistry; drug-free urine samples; good
habitual sleep, between 6.5–8.5 h daily duration with regular
bedtimes, and wake up times between 6–9 am (verified by sleep
logs and wrist actigraphy for at least one week before study entry);
absence of extreme morningness or extreme eveningness, as
assessed by questionnaire [24]; absence of sleep or circadian
disorders, as assessed by questionnaire [54] and polysomnography;
no history of psychiatric illness and no previous adverse
neuropsychiatric reaction to sleep deprivation; no history of
alcohol or drug abuse; and no current use of medical or drug
treatments (excluding oral contraceptives). The protocols were
approved by the Institutional Review Board of the University of
Pennsylvania. For all subjects, written informed consent was
obtained according to the principles expressed in the Declaration
of Helsinki prior to entry; all subjects received compensation for
participation.
Experimental Design
Subjects participated in either an 11 or 16 consecutive day
protocol in a controlled environment in the Sleep and Chrono-
biology Laboratory at the Hospital of the University of
Pennsylvania. For the current paper, only data from the first
seven nights of the protocols—which were procedurally identical
between studies—were analyzed to assess the role of the PER3
VNTR polymorphism on the effects of chronic PSD. For the first
two nights of the study (baseline), subjects received 10 h time in
bed from 2200–0800 h to reduce any pre-existing sleep debt; for
the subsequent five nights, subjects received 4 h time in bed per
night (0400–0800 h) for sleep.
Throughout the experiment, laboratory conditions were highly
controlled in terms of environmental conditions and scheduled
activities. Ambient light was fixed at ,50 lux during scheduled
wakefulness, and ,1 lux (darkness) during scheduled sleep.
Ambient temperature was maintained at 2261uC. Subjects were
continuously monitored by trained staff. Between performance
bouts, subjects were restricted from engaging in strenuous
activities, although they were allowed to read, play games, watch
movies, and interact with laboratory staff to help remain awake (no
visitors were permitted). Subjects received three standardized
meals per day, plus an optional healthy evening snack. Intake of
caffeine, turkey, bananas, alcohol or tobacco was prohibited.
Neurobehavioral Assessments
Subjects underwent computerized neurobehavioral tests every
2 h during scheduled wakefulness. The neurobehavioral test
battery included the following objective and subjective evaluations:
the Karolinska Sleepiness Scale (KSS), a Likert-type rating scale of
subjective sleepiness [29]; a computerized visual analog scale of
fatigue (VAS) anchored by ‘‘fresh as a daisy’’ and ‘‘tired to death’’
[30]; the digit symbol substitution task (DSST), a computerized
version of the cognitive performance task bearing the same name
in the Wechsler Adult Intelligence Scale [28]; the Digit Span (DS)
task, a test of working memory storage capacity, given in both the
forward and backward versions [28] and summed to produce a
total number correct measure for analysis; and the Psychomotor
Vigilance Task (PVT), a cognitive test of sustained attention
utilizing reaction times as an assay of behavioral alertness [25–27].
Subjects remained seated throughout the neurobehavioral test
periods and were behaviorally monitored. Subjects were instructed
to perform to the best of their ability and to use compensatory
effort to maintain performance. Daily values for each performance
task were calculated by averaging scores from all the test bouts that
day. Baseline values were determined from the second baseline
day’s performance.
Other Measurements
Before the study, subjects filled out a number of questionnaires
providing information on various demographics, sleep–wake and
circadian-related variables, and psychosocial/personality traits
which may predict responses to chronic PSD. These question-
naires included the Morningness-Eveningness Composite Scale
[24], the Beck Depression Inventory [22], and the Eysenck
Personality Inventory [23]. At baseline, subjects completed the
North American Adult Reading Test [21] as a measure of IQ. At
SR5, subjects were administered four executive function tests: the
Hayling test [32], the Brixton tests [32], the Controlled Oral Word
Association Test [33] and the Tower of London [34]. In addition,
in the 11-day protocol only, a modified version of the
Maintenance of Wakefulness Test [17,31]—a measure of the
ability to resist sleep—was administered once at baseline and once
at SR5, with a single MWT trial conducted between 1430–1600 h
on these two days. Before each trial, the lights were dimmed to
,10 lux and subjects were instructed to ‘‘keep your eyes open and
try not to fall asleep’’. Each trial was terminated at the first
occurrence of a microsleep (10 seconds of EEG theta activity) or at
30 minutes if sleep onset was not achieved. If subjects fell asleep
according to the microsleep criteria before the end of the 30-
minute trial, the number of minutes taken to fall asleep was
recorded. Subjects who failed to meet sleep onset criteria received
a MWT score of 30 minutes. For the MWT, the final available
sample sizes for analysis was as follows: PER3
4/4 (n=33), PER3
4/5
(n=46) and PER3
5/5 (n=11).
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Polysomnography. The PSG montage included frontal (Fz),
central (C3), and occipital (O2) EEG, bilateral EOG, submental
EMG, and ECG. Data were recorded from 2200 h (lights off) to
0800 h (lights on) during the second baseline night, and from
0400 h–0800 h on SR1 and on SR5. Sleep records were visually
scored in 30-sec epochs according to standard scoring criteria [55]
by a trained scorer. Equipment problems resulted in the loss of
some records at baseline, SR1 and SR5. Final sample sizes used
for analyses are listed in Table 3 (see footnote).
Non-REM EEG SWE and SWA. After artifact rejection,
spectral analysis of the sleep EEG was performed with Fast Fourier
Transform (FFT) in 5 sec bins. Power spectra were averaged
across 30 sec epochs. For each night, slow-wave energy (SWE) in
the delta band (0.5–4.5 Hz) was totaled over all epochs of non-
REM (visually-scored stages 2–4) sleep. Power in the delta band
(SWA) was then calculated by dividing SWE by the number of
NREM epochs. These procedures were applied to each of the
three EEG derivations (C3, Fz, O2). For the baseline night,
absolute values were determined for each hour of sleep for SWE
and SWA; for SR1 and SR5, SWE and SWA data were
normalized by calculating the percent of the corresponding hour
of the baseline night. For some records, EEG signal quality was
insufficient or contained too much artifact for reliable power
spectral analysis. Thus, the final sample sizes used for hourly
analyses were as follows: for baseline C3, PER3
4/4 (n=33), PER3
4/
5 (n=47), and PER3
5/5 (n=12); for baseline Fz, PER3
4/4 (n=41),
PER3
4/5 (n=46), and PER3
5/5 (n=11); for baseline O2, PER3
4/4
(n=41), PER3
4/5 (n=48), and PER3
5/5 (n=12); for SR1 and SR5
C3, PER3
4/4 (n=41), PER3
4/5 (n=47) and PER3
5/5 (n=12); for
SR1 and SR5 Fz, PER3
4/4 (n=43), PER3
4/5 (n=46) and PER3
5/5
(n=10); for SR1 and SR5 O2, PER3
4/4 (n=43), PER3
4/5 (n=44)
and PER3
5/5 (n=10).
Genotyping
Blood samples were collected for genetic analysis on the
morning following the second night of baseline sleep. Genomic
DNA was extracted from whole blood using Qiagen’s QIAamp
DNA Blood Mini Kit (Catalog #51106). Genotyping was
performed with polymerase chain reaction (PCR) using primers
as previously described by [48]. The amplification conditions were
as follows: 95uC for 15 minutes, then 30 cycles of 95uC for 1
minute, 60uC for 1 minute, and 72uC for 1 minute followed by
72uC for a 10-minute extension. The genotype of each subject
could be unambiguously determined.
Statistical Analyses
Mixed model analyses of variance (ANOVA), with day or hour
as the within-subjects (repeated measures) factor and genotype as
the between-group factor, were used to analyze the MWT, PSG,
SWA/SWE, PVT, KSS, VAS, DSST and DS data. Greenhouse–
Geisser corrections were applied to all within-subjects effects. One-
way ANOVA were used to analyze demographic and pre-study
measures, executive function measures, and PSG, MWT and
cognitive and sleep measures at baseline and during chronic PSD
(Tables 2 and 3). Post-hoc comparisons using Bonferroni-adjusted
probabilities examined significant group differences for all
measures. SPSS Statistical Software, version 15.0 (SPSS Inc.,
Chicago, IL, USA) was used for statistical analyses; p#0.05 was
considered significant.
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